12.2 Neonatal Jaundice: Physiological, Pathological & Kernicterus

Bilirubin Synthesis, Hepatic Processing & Enterohepatic Circulation

Neonatal jaundice (icterus neonatorum) affects up to 60% of healthy term infants and 80% of preterm infants during the first week of life. While the majority of cases represent benign, transitional physiological adaptation, extreme hyperbilirubinemia carries the devastating risk of permanent bilirubin-induced neurological dysfunction (BIND) and kernicterus. Clinicians practicing in Caribbean territories must possess a granular understanding of neonatal bilirubin kinetics, hemolytic disorders common in the region (notably G6PD deficiency and sickle cell disorders), and the critical distinctions between unconjugated and conjugated cholestatic liver disease.

Bilirubin Metabolism Pathway

1. Heme Catabolism: Approximately 75% of daily neonatal bilirubin originates from the breakdown of senescent circulating red blood cells (RBCs) in the reticuloendothelial system (spleen, liver, bone marrow), with the remaining 25% derived from ineffective erythropoiesis and tissue heme proteins (myoglobin, cytochromes, catalase). The microsomal enzyme heme oxygenase cleaves the protoporphyrin ring of heme, producing equimolar quantities of biliverdin, carbon monoxide, and iron. Biliverdin reductase subsequently reduces biliverdin to unconjugated (indirect) bilirubin.
2. Circulatory Transport: Unconjugated bilirubin is non-polar, highly lipophilic, and completely insoluble in water at physiological pH. It binds reversibly to circulating serum albumin (one mole of albumin binds one mole of bilirubin tightly at a high-affinity site). Only the unbound, lipophilic "free" bilirubin fraction is capable of traversing cellular membranes, including the blood-brain barrier and hepatocyte sinusoidal membranes.
3. Hepatic Uptake & Glucuronidation: Free bilirubin dissociates from albumin at the sinusoidal surface and enters hepatocytes via passive diffusion and facilitated uptake by Organic Anion Transporting Polypeptides (OATP1B1 and OATP1B3). Intracellularly, bilirubin binds to cytosolic ligandin (Y-protein / glutathione S-transferase B) to prevent reflux back into the circulation. In the endoplasmic reticulum, the enzyme uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) catalyzes the conjugation of glucuronic acid to bilirubin, forming water-soluble bilirubin monoglucuronide and diglucuronide (conjugated / direct bilirubin).
4. Biliary Excretion & Enterohepatic Circulation: Conjugated bilirubin is actively pumped across the canalicular membrane into the biliary tree via an ATP-dependent transporter, Multidrug Resistance-associated Protein 2 (MRP2). Upon entering the small intestine via the ampulla of Vater, conjugated bilirubin cannot be reabsorbed across the intestinal mucosa. In adults, anaerobic colonic microflora reduces conjugated bilirubin into colourless stercobilinogen and urobilinogen. In neonates, however, three unique physiological differences exist:
   • The neonatal gut lumen is relatively sterile, lacking bacterial flora to reduce bilirubin.
   • The neonatal intestinal brush border contains high concentrations of the enzyme beta-glucuronidase, which hydrolyzes water-soluble conjugated bilirubin back into lipophilic unconjugated bilirubin.
   • This deconjugated bilirubin is readily reabsorbed across the intestinal enterocytes into the mesenteric portal blood, returning directly to the liver—a recycling process termed the enterohepatic circulation of bilirubin.

Why Neonates Are Prone to Hyperbilirubinemia

Neonates experience a physiological imbalance between bilirubin production and clearance due to four distinct physiological mechanisms:

1. Higher Red Blood Cell Mass: Neonates have an elevated hematocrit (55% to 65%) and a circulating blood volume of 80 to 85 mL/kg, yielding a daily bilirubin production rate (6 to 8 mg/kg/day) that is more than double that of an adult (3 to 4 mg/kg/day).
2. Shortened Erythrocyte Lifespan: Fetal erythrocytes survive only 70 to 90 days compared to 120 days for adult erythrocytes.
3. Deficient Hepatic UGT1A1 Activity: At birth, hepatic UGT1A1 enzyme activity is only 0.1% to 1% of adult levels, reaching adult capacity only after 6 to 14 weeks of life.
4. Enhanced Enterohepatic Recirculation: High mucosal beta-glucuronidase activity combined with sluggish gut motility and delayed meconium passage markedly amplifies bilirubin reabsorption.

Physiological vs. Pathological Jaundice: The Diagnostic Criteria

Jaundice becomes clinically visible when total serum bilirubin (TSB) exceeds 5 to 7 mg/dL (85 to 120 umol/L). In neonates, dermal icterus progresses in a predictable cephalocaudal direction (Kramer's zones): face (~5 mg/dL), upper trunk (~10 mg/dL), lower abdomen and thighs (~12 mg/dL), forearms and lower legs (~15 mg/dL), and palms and soles (> 15 to 20 mg/dL). While Kramer scoring provides a rough bedside estimate, visual inspection notoriously underestimates bilirubin severity in deeply pigmented Caribbean neonates; therefore, quantitative transcutaneous bilirubinometry (TcB) or Total Serum Bilirubin (TSB) measurement is mandatory for clinical decision-making.

Criteria Defining Physiological Jaundice

Physiological jaundice is a benign, self-limiting transitional state fulfilling ALL of the following criteria:

• Appears AFTER 24 hours of life (typically on day 2 or 3).
• Peaks on day 3 to 5 in term infants (TSB usually < 12 to 15 mg/dL [205 to 255 umol/L]) and on day 5 to 7 in preterm infants (TSB < 15 mg/dL).
• The rate of rise does NOT exceed 5 mg/dL/day (85 umol/L/day) or 0.2 mg/dL/hour (3.4 umol/L/hour).
• It is predominantly unconjugated (indirect): direct bilirubin is not elevated (>1.0 mg/dL [17 umol/L] warrants evaluation, irrespective of its percentage of TSB).
• Resolves spontaneously by day 10 to 14 in term infants, and by day 21 in preterm infants.
• The infant remains vigorous, feeds well, exhibits normal stool and urine colour, and shows no hepatosplenomegaly.

The Mandatory Red Flags Defining Pathological Jaundice

Hyperbilirubinemia must be classified as pathological and investigated emergently if ANY of the following features are present:

1. Appearance within the FIRST 24 HOURS of life: Any visible jaundice or elevated TSB in the first 24 hours is ALWAYS pathological until proven otherwise, reflecting accelerated hemolysis (Rh/ABO isoimmunization, G6PD deficiency) or intrauterine infection.
2. Rapid Rate of Rise: Total serum bilirubin increasing faster than 5 mg/dL/day (85 umol/L/day) or > 0.2 mg/dL/hour (3.4 umol/L/hour).
3. Elevated Direct Bilirubin (Cholestasis): A direct bilirubin >1.0 mg/dL (17 umol/L) warrants evaluation regardless of the total bilirubin or percentage. A rising direct fraction strengthens concern for hepatobiliary disease; conjugated hyperbilirubinemia is not physiological.
4. Prolonged Duration: Clinical jaundice persisting beyond 14 days of life in a term infant, or beyond 21 days in a preterm infant.
5. Excessive Peak Bilirubin: TSB crossing the gestational-age/hour-specific phototherapy or exchange treatment threshold. The Bhutani predictive risk nomogram is not a treatment chart.
6. Signs of Concurrent Systemic Disease: Lethargy, poor feeding, temperature instability, vomiting, pallor, petechiae, hepatosplenomegaly, dark tea-colored urine, or pale/acholic (clay-colored) stools.

Etiological Framework: Unconjugated vs. Conjugated Hyperbilirubinemia

Clinical Appraisal of Key Caribbean Entities

1. ABO Incompatibility

Occurs in approximately 15% to 20% of all pregnancies, typically when a Group O mother carries a Group A or Group B fetus. Group O mothers possess naturally occurring, high-titer anti-A and anti-B IgG antibodies that readily cross the placenta into fetal circulation, binding to fetal A or B surface antigens. Although common, clinically severe hemolysis occurs in only a fraction of cases because A and B carbohydrate antigens are weakly expressed on neonatal erythrocytes and are widely distributed across vascular endothelial and placental tissues, absorbing maternal antibodies. The Direct Antiglobulin Test (DAT / Coombs) is often weakly positive or negative, and the peripheral blood film classically displays microspherocytes.

2. Rhesus (RhD) Isoimmunization

Develops when an RhD-negative mother is sensitized to RhD-positive fetal erythrocytes during a previous pregnancy, miscarriage, or invasive obstetric procedure. In subsequent RhD-positive pregnancies, maternal high-affinity anti-D IgG antibodies cross the placenta, mediating intense, complement-independent extravascular hemolysis by splenic macrophages. Clinically manifests as severe jaundice in the first 24 hours, profound regenerative anemia, marked reticulocytosis (> 10% to 20%), erythroblastosis (numerous nucleated RBCs on smear), hepatosplenomegaly from compensatory extramedullary hematopoiesis, strongly positive DAT, and potentially fatal hydrops fetalis (anasarca, pericardial/pleural effusions, high-output heart failure). Prevention relies on routine administration of Anti-D Immunoglobulin (RhoGAM) at 28 weeks and within 72 hours of delivery.

3. Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency

G6PD deficiency is an X-linked recessive enzymopathy that affects the rate-limiting enzyme of the hexose monophosphate (HMP) shunt. G6PD generates NADPH, which maintains reduced glutathione (GSH)—the primary intracellular defense against oxidative membrane injury in erythrocytes. G6PD deficiency affects up to 15% to 25% of males in parts of the Caribbean (due to historical positive selection against severe Plasmodium falciparum malaria). Unlike the classic adult picture of hemolysis triggered by fava beans, oxidant drugs (sulfonamides, primaquine), or infections, neonatal G6PD deficiency frequently causes spontaneous, unpredictable, explosive hyperbilirubinemia between days 2 and 5 of life, even in the absence of an identifiable oxidative trigger, primarily driven by impaired hepatic bilirubin clearance combined with low-grade hemolysis. Peripheral blood smears demonstrate Heinz bodies (precipitated oxidized hemoglobin) and "bite cells" (degmacytes). Quantitative G6PD enzyme assays may be falsely normal during acute hemolytic crises because old enzyme-deficient RBCs have hemolyzed, leaving behind young reticulocytes with higher enzyme levels; repeat testing at 2 to 3 months is mandatory.

4. Breastfeeding Failure Jaundice vs. Breast Milk Jaundice

• Breastfeeding Failure Jaundice (Lactation Jaundice): Occurs in the first week of life (days 2 to 5) due to insufficient breast milk intake, suboptimal latch, or delayed lactogenesis II. The neonate exhibits dehydration, weight loss exceeding 7% to 10% of birth weight, oliguria, and infrequent stooling. Inadequate enteral intake slows gastrointestinal transit, drastically accelerating the enterohepatic circulation of bilirubin. Management: Correct lactation technique, increase feeding frequency to 8 to 12 times in 24 hours, and provide supplemental expressed breast milk or formula if dehydration is severe. Do not give water or glucose water.
• Breast Milk Jaundice: Appears later, usually after day 4 to 7, peaking during the 2nd to 3rd week of life, and can persist for 6 to 12 weeks. The infant is completely healthy, afebrile, vigorous, and gaining weight rapidly on exclusive breastfeeding, with normal pale-yellow stools. It is caused by factors in maternal milk (high concentrations of beta-glucuronidase, non-esterified free fatty acids, and epidermal growth factor) that competitively inhibit hepatic UGT1A1 and augment intestinal deconjugation. Management: Reassure parents and continue exclusive breastfeeding. Temporary cessation of breastfeeding is unnecessary and harmful.

5. Biliary Atresia: The Surgical Emergency

Biliary atresia is an idiopathic, progressive, inflammatory obliteration of the extrahepatic biliary tree that leads to biliary cirrhosis, portal hypertension, and liver failure. It affects 1 in 10,000 to 18,000 live births. It is the leading indication for paediatric liver transplantation worldwide.

• Clinical Hallmarks: Full-term, thriving infants who develop progressive jaundice between 2 and 6 weeks of age, accompanied by acholic (chalky-white or pale clay-colored) stools and dark amber, tea-colored urine (due to water-soluble conjugated bilirubin excretion). Firm hepatomegaly develops as fibrosis progresses.
• Diagnostic Protocol: Serum testing reveals conjugated (direct) hyperbilirubinemia with elevated Gamma-Glutamyl Transferase (GGT) and alkaline phosphatase. Abdominal ultrasound performed after a 4-hour fast demonstrates an absent or contracted, non-distensible gallbladder and the pathognomonic "triangular cord sign" (a triangular or band-like echogenic fibrous density > 4 mm anterior to the portal vein bifurcation). Intraoperative cholangiography provides definitive confirmation.
• Definitive Treatment: The Kasai portoenterostomy (hepatoportoenterostomy), where the atretic extrahepatic ductal tissue is excised and a Roux-en-Y jejunal loop is anastomosed directly to the denuded hepatic porta hepatis to establish bile drainage. Surgical timing is critical: the procedure must be executed BEFORE 60 days of life (success rate > 70% to 80% if done < 60 days; drops below 20% to 30% if performed after 80 to 90 days, leading to irreversible biliary cirrhosis requiring liver transplantation).

Bilirubin-Induced Neurologic Dysfunction (BIND) & Kernicterus

Lipophilic unconjugated free bilirubin crosses the blood-brain barrier when serum concentrations exceed albumin-binding capacity, or when the blood-brain barrier is disrupted by prematurity, acidosis, hypoxia, sepsis, or rapid hyperosmolar shifts. Bilirubin exerts neurotoxic effects by disrupting mitochondrial respiration, uncoupling oxidative phosphorylation, provoking intracellular calcium influx, and inducing neuronal apoptosis.

Anatomical Vulnerability

Bilirubin exhibits selective tropism for specific deep cerebral structures:

• Basal Ganglia: Primarily the globus pallidus and subthalamic nucleus.
• Brainstem Auditory Nuclei: Including the cochlear nuclei and superior olivary complex.
• Oculomotor Nuclei: Cranial nerves III, IV, and VI within the midbrain and brainstem.
• Cerebellum: Specifically cerebellar Purkinje cells and dentate nuclei.

1. Acute Bilirubin Encephalopathy (ABE)

Represents the acute clinical manifestations of bilirubin neurotoxicity in the newborn, traditionally divided into three progressive phases:

• Phase 1 (Early / Reversible): Lethargy, hypotonia, weak sucking reflex, decreased spontaneous movement, high-pitched whimper. Prompt intensive phototherapy or exchange transfusion at this stage can reverse neurotoxicity completely.
• Phase 2 (Intermediate / Progressive): Stupor, marked irritability, fluctuating tone with hypertonia, retrocollis (spasmodic backward arching of the neck), opisthotonos (severe backward arching of the trunk), high-pitched piercing cry, and fever.
• Phase 3 (Advanced / Irreversible): Pronounced, persistent opisthotonos and retrocollis, shrill cry, refusal to feed, bicycling/athetoid limb posturing, apnea, intractable seizures, stupor progressing to coma, and death. Surviving infants invariably develop chronic kernicterus.

2. Chronic Bilirubin Encephalopathy (Kernicterus)

Refers to the permanent, disabling, long-term neurodevelopmental sequelae resulting from chronic bilirubin toxicity:

1. Choreoathetoid Cerebral Palsy: Involuntary, slow, writhing movements (athetosis) and rapid jerking movements (chorea) involving all extremities, neck, and face, caused by destruction of the globus pallidus.
2. Sensorineural Hearing Loss: Auditory neuropathy spectrum disorder (ANSD), characterized by absent or severely abnormal Brainstem Auditory Evoked Responses (BAER) despite normal outer hair cell function on Otoacoustic Emissions (OAE).
3. Upward Gaze Palsy: Impairment of vertical conjugate upward eye movement (Parinaud-like syndrome), forcing infants into a permanent "setting-sun" resting posture.
4. Dental Enamel Dysplasia: Severe green pigmentation (chlorodontia) and transverse hypoplastic enamel ridging of the deciduous (primary) teeth.

Therapeutic Management: Phototherapy & Exchange Transfusion

Use the relevant gestational-age/hour-specific treatment chart, adjusted for neurotoxicity risks such as haemolysis, sepsis, clinical instability or albumin<3 g/dL. The AAP 2022 charts apply to infants>=35 weeks; younger infants need a preterm protocol. For the AAP pathway, TSB within 2 mg/dL of the exchange threshold requires urgent escalation: intensive phototherapy, IV hydration, neonatal consultation/transfer and TSB at least every 2 hours. Exchange-level TSB or intermediate/advanced encephalopathy requires urgent exchange assessment.

1. Intensive Phototherapy

• Mechanism: Skin is exposed to narrow-spectrum blue-green light in the peak wavelength of 460 to 490 nm. Photons penetrate the dermal and subcutaneous capillary beds, interacting with lipophilic unconjugated (4Z,15Z)-bilirubin to induce three distinct photochemical reactions:
  1. Structural Isomerization (Primary Therapeutic Pathway): Irreversible intramolecular cyclization converting native bilirubin into lumirubin. Lumirubin is highly water-soluble, requires no hepatic conjugation, and is excreted rapidly into bile and urine. This pathway is responsible for the vast majority of phototherapy-mediated bilirubin decline.
  2. Configurational Photoisomerization: Reversible geometric photo-conversion of native (4Z,15Z)-bilirubin into the (4Z,15E) isomer, which is excreted into bile but can revert back into native bilirubin if gut transit is prolonged.
  3. Photo-oxidation: Cleaves bilirubin into small colourless polar pyrrolic fragments excreted in urine (minor pathway).
• Clinical Application: Use high-intensity LED systems delivering irradiance >= 30 microW/cm2/nm. Maximize body surface area exposure (naked except for small diaper and opaque eye shields to prevent permanent retinal photochemical injury). Ensure adequate enteral hydration.
• Adverse Effects: Increased insensible water loss (monitor hydration and individualize any additional fluid), hypothermia or hyperthermia, benign loose green watery stools, transient erythematous rash, and Bronze Baby Syndrome (a dark greyish-brown discoloration of skin, serum, and urine that can occur during phototherapy in cholestatic infants and usually resolves. Phototherapy does not lower conjugated bilirubin, but cholestasis does not preclude treating coexisting unconjugated hyperbilirubinemia).

2. Double-Volume Exchange Transfusion (DVET)

• Indications: Urgent exchange transfusion for TSB at or above the age/gestation/risk-specific exchange threshold, or intermediate/advanced acute bilirubin encephalopathy regardless of TSB. Continue intensive phototherapy while preparing. If TSB falls below the exchange threshold before starting and there are no such neurological signs, a specialist may defer exchange with continued escalation care and 2-hourly TSB monitoring.
• Volume: Double the circulating blood volume = 160 to 180 mL/kg in term infants (180 to 200 mL/kg in preterm). This replaces 85% to 90% of circulating erythrocytes with fresh donor cells, clears circulating maternal anti-erythrocyte antibodies, and reduces total serum bilirubin concentrations by approximately 50%.
• Donor Blood Selection:
  • Rh Incompatibility: ABO-compatible with the infant, RhD-negative, CMV-negative, irradiated, crossmatched against maternal serum.
  • ABO Incompatibility: Group O red cells suspended in Group AB plasma (or Rh-compatible Group O whole blood).
• Technique: Performed via an umbilical venous catheter using an isovolumetric push-pull technique in small aliquots (5 mL/kg, maximum 10 to 20 mL per pass in term infants) over 90 to 120 minutes.
• Complications: Acute hypocalcemia (citrate anticoagulant binds free calcium; monitor ionized calcium and correct hypocalcemia under the neonatal protocol rather than giving routine calcium), hyperkalemia (use fresh blood < 5 days old), cardiac arrest, air embolism, thrombocytopenia, portal vein thrombosis, and necrotizing enterocolitis.

3. Intravenous Immunoglobulin (IVIG)

• Indication (AAP pathway, >=35 weeks): IVIG 0.5–1 g/kg over 2 hours may be considered for DAT-positive isoimmune haemolytic disease when TSB reaches/exceeds the escalation threshold (2 mg/dL below exchange), particularly if bilirubin rises despite intensive phototherapy or timely exchange is difficult. It is not routine treatment; it may be repeated after 12 hours under specialist direction.
• Rationale & Limits: IVIG may reduce Fc-mediated destruction of antibody-coated red cells, but its ability to prevent exchange transfusion is uncertain and adverse effects, including NEC, are a concern. Continue intensive phototherapy, frequent TSB checks and exchange preparation; IVIG must not delay indicated exchange transfusion.